Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
- 1 April 2002
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 52 (5) , 1293-1302
- https://doi.org/10.1016/s0360-3016(01)02740-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic indexSeminars in Oncology, 2001
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- Toxicity and Efficacy of Concurrent Gemcitabine and Radiotherapy for Locally Advanced Pancreatic CancerJournal of Gastrointestinal Cancer, 2001
- Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 1999
- Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft modelRadiation Oncology Investigations, 1997
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancerInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreasInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Intraoperative and external beam irradiation ± 5-FU for locally advanced pancreatic cancerInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Intraoperative radiation therapy for patients with pancreatic carcinomaWorld Journal of Surgery, 1984